How overweight do you need to be to use Wegovy in the UK?

You've checked your BMI, here's what the licence actually says

Picture the moment: you've put your height and weight into the NHS BMI calculator and you're looking at a number in the 27–29 range. Maybe you've heard Wegovy described as something only for people with severe obesity, and you're unsure whether your situation qualifies. The short answer is that it can, but only if you also have at least one weight-related health condition alongside that BMI.

The conditions that count include type 2 diabetes, prediabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea, and similar metabolic or cardiovascular problems that excess weight contributes to. Osteoarthritis and non-alcoholic fatty liver disease are also recognised in clinical practice. If your BMI sits between 27 and 29.9 and you have none of these, you would not currently fall within the licensed criteria for Wegovy.

At BMI 30 and above, no additional condition is required by the licence itself. That said, your prescriber will still review your complete health picture, existing conditions, any medicines you take, and whether anything in your history makes semaglutide unsuitable. If you want to understand exactly how BMI maps onto Wegovy eligibility, there is more detail on that dedicated page. Worth noting: BMI is a population measure, not a perfect tool. It is where eligibility assessment starts, not where it ends.

When ethnic background changes the numbers

For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the standard BMI thresholds tend to overestimate the body fat level at which health risk rises. UK guidance reflects this. The adjusted figures sit approximately 2.5 kg/m² lower than the headline thresholds, so roughly BMI 27.5 for the upper tier and around 25 for the lower one, subject to the same condition requirement.

This is not a separate licence; it is a clinical adjustment that prescribers apply when reviewing your case. If you are in one of these groups and your BMI falls slightly below 30, it is worth raising this during your consultation rather than assuming you do not qualify. The thresholds explained in more depth here set this out clearly.

The NICE recommendation for Wegovy on the NHS (TA875) quotes the same ethnic-background adjustment and specifies that treatment should take place within a specialist weight management service, with a two-year maximum. Private prescribing follows the licensed criteria rather than the NICE commissioning restriction, which is why people who do not meet the NHS route's additional requirements can still access treatment privately when clinically appropriate. A prescriber decides that, not a form, and not an algorithm.

How much does being only slightly overweight change the picture?

This is one of the questions our prescribers hear regularly. If your BMI is in the 27–29.9 bracket and you do have a qualifying condition, you can find out whether Wegovy is suitable when you are only slightly overweight, including what the licence says for people in exactly that position. You can read more about the clinical evidence behind once-weekly semaglutide in adults with overweight or obesity, which explains the research this licence rests on, including the STEP 1 trial published in the New England Journal of Medicine that involved participants with a BMI of 27 or above with at least one weight-related condition alongside the higher-BMI group.

If your BMI is below 27, Wegovy is not licensed for you. The medicine is also not recommended during pregnancy, breastfeeding, or when trying to conceive, and it is not licensed for under-18s. A history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 would also rule it out. These are not grey areas; they are hard boundaries the prescriber will check.

For those sitting just above the BMI threshold with no comorbidities, there is a separate question worth considering, whether the clinical benefit justifies treatment at that point, or whether lifestyle changes alone might be the right first step. That conversation belongs with a prescriber. If you are wondering how overweight you need to be for Wegovy to be appropriate, that page goes into detail for people in exactly this situation, including those who are only slightly overweight.

The private route versus the NHS, and what happens next

On the NHS, Wegovy is available only through specialist weight management services under the NICE TA875 recommendation, and waiting lists in many areas are long. The NHS England guidance on weight management injections sets out what wraparound diet and activity support is required alongside treatment. Meeting the BMI criteria does not put you at the front of the queue; service capacity and local commissioning decisions do.

Private prescribing follows the licensed criteria rather than the NHS commissioning rules. If you qualify under the licence and a prescriber agrees you are suitable, treatment can begin quickly. At nume, consultations are reviewed the same day by a GPhC-registered prescriber (a real clinician, not software) and if approved, your prescription is dispatched the same day for free next-working-day delivery. A lot of people place their consultation on a Monday morning, or just after payday, and have their first pen arrive on Tuesday. The process is straightforward once eligibility is confirmed.

If you want to understand the cost side of things before you start, the Wegovy price comparison page covers what private treatment typically costs in the UK and what to look for in any provider you consider. When you're ready to find out whether you qualify, speaking to our prescribers is the starting point.